1. In Vivo

Gender Diversity In Pharma: Caught Between Desire And Reality

Charting The Executive Gender Mix Across 384 Companies

 
• By John Hodgson

Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete. 

Group
talent does not reside solely within the confines of one gender, color or ethnic background • Source: Shutterstock

Pharma as an industry suffers from cerebral dysmorphia: the structure of its head does not always match its body. The industry is struggling to align its executive management layer with the diversity in its workforce. There are short-term, symptomatic fixes for the condition but curative therapy is a protracted process that, at current rates, will take until 2050 to complete.

Beth Crowley is now senior vice president and chief product development officer at Celldex Therapeutics Inc., a clinical-stage antibody and immuno-oncology company in Hampton, New Jersey. But she started...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

More from In Vivo

The 360 Degrees Of European Biotech Financing In 2025

 
• By Jo Shorthouse

Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.

Rising Leaders 2025: Pedro Valencia’s ADC Vision At AbbVie

 
• By Jo Shorthouse

From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.

Leaders At The Frontier: Conversations From SynBioBeta 2025

 
• By David Wild

Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.